Mankind Pharma launches hypertension drug at Rs 7.5 per tablet

Published On 2017-05-18 06:01 GMT   |   Update On 2017-05-18 06:01 GMT

New Delhi: Mankind Pharma said it has launched anti-hypertensive drug Zolahart at an affordable price of Rs 7.50 per tablet.


Aiming at reducing the most commonly related disease of hypertension, the introduction of Zolahart (Azilsartan) at 51 per cent less price, is done with the mission of achieving the prime objective of – world class quality at most affordable price.


Azilsartan, a new generation anti-hypertensive drug, offers potent and persistent 24 hours’ blood pressure control. It is proven to be safe for hypertensive patients with comorbid conditions like diabetes or Chronic Kidney Disease (CKD). The recently launched Angiotensin-receptor-blocker (Azilsartan) is the most potent amongst ARBs and is expected to reduce the proportion of patients of uncontrolled BP considerably.


"At Mankind, we endeavour to bring the latest innovative therapies with assured quality that address primary healthcare challenge in India-world class quality at an affordable price. It is with this thought, we decided to launch Zolahart (Azilsartan), the latest anti-hypertensive drug at the most affordable price of 7.50/Tab," Mankind Group chairman and founder R C Juneja said in a statement.


The company said the price of its product was 51 per cent lower than that of the other competitor drugs in the segment.

Article Source : PRESS RELEASE

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News